FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 355:1409-1412 October 5, 2006 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Interview Editorial by Stone, E. M. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Rosenfeld, P. J. Related Article by Brown, D. M. Related Article by de Jong, P. T.V.M. PubMed Citation

On June 30, 2006, the Food and Drug Administration (FDA) approved ranibizumab — which is manufactured by Genentech and marketed as Lucentis — for the treatment of neovascular age-related macular degeneration. Ranibizumab is a fragment of a recombinant monoclonal antibody (see Figure 1) that binds to and inhibits all the biologically active forms of vascular endothelial growth factor A. Administered by injection into the vitreous cavity (see Figure 2), ranibizumab prevents vision loss and improves visual acuity, with few serious adverse effects (as indicated in the reports by Rosenfeld et al. and Brown et al. in this issue . . . [Full Text of this Article]

Source Information

Dr. Steinbrook (rsteinbrook@attglobal.net) is a national correspondent for the Journal.

An interview with Dr. Frederick L. Ferris III, clinical director of the National Eye Institute, can be heard at www.nejm.org.

This article has been cited by other articles:

• Moreno, S F., Paloma, J B. (2008). Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy. Br. J. Ophthalmol. 92: 866-867 [Full Text]  
• Campa, C., Kasman, I., Ye, W., Lee, W. P., Fuh, G., Ferrara, N. (2008). Effects of an Anti-VEGF-A Monoclonal Antibody on Laser-Induced Choroidal Neovascularization in Mice: Optimizing Methods to Quantify Vascular Changes. IOVS 49: 1178-1183 [Abstract] [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Grim, P., Hunkler, R. J., Hontz, K. M., Schumock, G. T. (2008). Projecting future drug expenditures--2008. Am J Health Syst Pharm 65: 234-253 [Abstract] [Full Text]  
• Rennie, C. A, Hannan, S., Maycock, N., Kang, C. (2007). Age-related macular degeneration: what do patients find on the internet?. JRSM 100: 473-477 [Abstract] [Full Text]  
• Raftery, J., Clegg, A., Jones, J., Tan, S. C., Lotery, A. (2007). Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br. J. Ophthalmol. 91: 1244-1246 [Abstract] [Full Text]  
• Manzano, R. P A, Peyman, G. A, Khan, P., Carvounis, P. E, Kivilcim, M., Ren, M., Lake, J. C, Chevez-Barrios, P. (2007). Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br. J. Ophthalmol. 91: 804-807 [Abstract] [Full Text]  
• Kolodgie, F. D., Narula, J., Yuan, C., Burke, A. P., Finn, A. V., Virmani, R. (2007). Elimination of Neoangiogenesis for Plaque Stabilization: Is There a Role for Local Drug Therapy?. J Am Coll Cardiol 49: 2093-2101 [Abstract] [Full Text]  
• Liew, G., Mitchell, P., Gillies, M. C., Wong, T. Y., Rosenfeld, P. J., Brown, D. M., Schneider, S., the MARINA and ANCHOR Study Groups, (2007). Ranibizumab for Neovascular Age-Related Macular Degeneration. NEJM 356: 747-750 [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Schumock, G. T., Grim, P., Hunkler, R. J., Hontz, K. M. (2007). Projecting future drug expenditures--2007. Am J Health Syst Pharm 64: 298-314 [Abstract] [Full Text]  
• (2006). New Treatment for Age-Related Macular Degeneration. JWatch General 2006: 1-1 [Full Text]